WO2021262147A1 - Dispositifs et procédés de traitement de sang total en ligne - Google Patents

Dispositifs et procédés de traitement de sang total en ligne Download PDF

Info

Publication number
WO2021262147A1
WO2021262147A1 PCT/US2020/039056 US2020039056W WO2021262147A1 WO 2021262147 A1 WO2021262147 A1 WO 2021262147A1 US 2020039056 W US2020039056 W US 2020039056W WO 2021262147 A1 WO2021262147 A1 WO 2021262147A1
Authority
WO
WIPO (PCT)
Prior art keywords
whole blood
channel
conduit
treatment device
blood treatment
Prior art date
Application number
PCT/US2020/039056
Other languages
English (en)
Inventor
Michael Poirier
Original Assignee
Qualigen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qualigen Inc. filed Critical Qualigen Inc.
Priority to PCT/US2020/039056 priority Critical patent/WO2021262147A1/fr
Publication of WO2021262147A1 publication Critical patent/WO2021262147A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/203—Equilibration or regeneration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/26—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes and internal elements which are moving
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/75—General characteristics of the apparatus with filters
    • A61M2205/7554—General characteristics of the apparatus with filters with means for unclogging or regenerating filters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/491—Blood by separating the blood components

Definitions

  • the field of the invention is treatment of whole blood, especially as it relates to in vivo continuous removal of one or more components contained in whole blood.
  • Removal of various undesirable components from whole blood is well known and often includes ex vivo separation of cellular components (e.g., centrifugation or filtration) to obtain a cell-free fluid that is then processed, typically using affinity media and/or enzymatic treatment. While such treatment is standard practice in many instances, hemolysis is often a problem. Still more disadvantageously, such known treatment typically requires relatively large equipment and is therefore impractical in ambulatory use.
  • the present inventive subject matter is directed to diagnostic and therapeutic devices in which whole blood is passed through one or more channels of a rotating or reciprocating element wherein the channels comprise an affinity agent to allow specific binding of a target compound to the channel. Due to the rotating or reciprocating motion of the element, the channel can be moved into and out of fluid communication with the circulatory system of a mammal such that the affinity agent binds the target compound when the channel is in fluid communication with the circulatory system and such that bound target antigen can be removed from the affinity agent when the channel is removed from the fluid communication with the circulatory system and in fluid communication with a regeneration circuit.
  • the rotating or reciprocating element has multiple channels and is configured as a rotating wheel, and multiple conduits are separately provided to the channels in the wheel to allow concurrent adsorption of the target compound to one channel while regenerating the affinity agent in another channel.
  • the element may also be configured as an Archimedean screw or a reciprocating piston. Consequently, it should be recognized a target compound can be continuously removed from the blood stream on-line and in vivo as such devices and methods allow for multiple passes of whole blood through the device without saturating the affinity agent.
  • contemplated devices will therefore include a first conduit, a second conduit, and a rotating or reciprocating element having a channel, wherein the first and second conduits are fluidly coupled to the rotating or reciprocating element such that the channel is fluidly continuous with the first conduit when the channel is fluidly discontinuous with the second conduit, and such that the channel is fluidly discontinuous with the first conduit when the channel is fluidly continuous with the second conduit.
  • the first conduit is preferably configured to receive whole blood (directly from the circulation in an on-line mode, or indirectly, via blood collection bag or other implement), and the second conduit is preferably configured to receive a regeneration fluid (typically from a reservoir or device that prepares the regeneration fluid in situ).
  • the channel will have a surface that is modified with an affinity agent (most typically an antibody or antibody fragment, a nucleic acid or nucleic acid analog, a lectin, etc.) at a concentration effective to allow removal of a target compound from whole blood, wherein the target compound is capable of binding with high specificity and affinity to the affinity agent.
  • an affinity agent most typically an antibody or antibody fragment, a nucleic acid or nucleic acid analog, a lectin, etc.
  • Figure 1 A depicts an exemplary device in which the rotating or reciprocating element is configured as a wheel having a plurality of conduits extending through the wheel.
  • the wheel is preferably rotatably coupled to at least two conduits, which are here indicated as half-pipes with abutting surfaces to so form a cylindrical structure.
  • the wheel is disposed in the middle of the conduits such that flow of whole blood enters the upper conduit at the site marked 'whole blood inlet', passes through the upper three channels that are coated with an antibody (e.g., specific against IL-8), and continues to flow through the upper half-pipe to exit at the site marked 'whole blood outlet'. During this pass, target compounds will bind to the affinity agents.
  • flow of regeneration fluid enters the lower conduit at the site marked 'regen fluid inlet', passes through the lower three channels and causes the bound target compounds to elute into the regeneration fluid, which flows through and exits the lower half-pipe to leave the pipe at the site marked 'regen fluid outlet'.
  • the wheel will rotate during operation, preferably at a speed that will allow saturation of the affinity agents with the target compound during the presence of the channel in the upper half-pipe. Once saturated, and due to the preferably continuous rotation of the wheel, the channel with the saturated affinity agents will enter the lower half-pipe and is then exposed to the regeneration fluid for regeneration of the affinity agent. Once regenerated, and due to the preferably continuous rotation of the wheel, the channel with the regenerated affinity agents will enter the lower half-pipe and is once again available for a new cycle of binding and regeneration.
  • the rotating or reciprocating element is configured as a Archimedean screw that fittingly extends through the length of a cylindrical main pipe.
  • two fluid conduits join the main pipe in a manner such that (a) fluid entering on one branch of the main pipe is pumped along the pipe and exits one of the two joining conduits, and (b) fluid entering the other of the two joining conduits is pumped into and along the other branch and exits the other branch.
  • the channel is formed by the helical groove of the screw and is also coated with (or otherwise coupled to) an affinity agent.
  • the moving element may also be configured as a reciprocating piston with one or more channels extending through the piston as exemplarily illustrated in Figure 1C.
  • the piston has a plurality of channels where two channels are concurrently employed for binding and absorption.
  • the regenerated channel is moved into the flow of whole blood as the binding channel is saturated.
  • Figure 1C shows an additional channel which may be employed for measurement of an analyte and/or dispensation of a pharmaceutical agent.
  • contemplated methods include a step of moving the whole blood through a channel in a rotating or reciprocating element while the channel is fluidly coupled to a first conduit that contains the whole blood, wherein the channel comprises a surface that is modified with an affinity agent at a concentration effective to allow removal of a target compound from whole blood.
  • the rotating or reciprocating element is moved into a position such that the channel is fluidly disconnected from the first conduit and fluidly connected with a second conduit, and in yet another step, the target compound is eluted from the surface while the channel is fluidly connected with the second conduit.
  • the rotating or reciprocating element is then further moved into a position such that the channel is fluidly connected with the first conduit and fluidly disconnected with the second conduit.
  • the affinity agent in contemplated devices and methods is continuously or intermittently regenerated, it should also be appreciated that the affinity agent may be saturated and then discarded (e.g., via user replacement of the rotating or reciprocating element, or via replacement of the channel where the channel is configured as a cylinder).
  • a whole blood treatment device may include a first conduit, a sealing area, and a rotating or reciprocating element having a channel, wherein the first conduit is fluidly coupled to the rotating or reciprocating element such that the channel is fluidly continuous with the first conduit when the channel is fluidly discontinuous with the sealing area, and such that the channel is fluidly discontinuous with the first conduit when the channel is fluidly continuous with the sealing area.
  • the first conduit is configured to receive whole blood
  • the sealing area is configured to allow flow-less incubation of the whole blood in the channel when the channel is fluidly continuous with the sealing area.
  • a volume of whole blood is captured in the channel while the channel is in contact with the sealing area to so allow binding of a target compound from an essentially non-moving or non-flowing volume of whole blood.
  • Such incubation is considered to improve binding efficiency, especially where the volume-to-surface ratio is relatively high.
  • the channel will include a surface that is modified with an affinity agent at a concentration effective to allow removal of a target compound from whole blood.
  • the rotating or reciprocating element is disposable and/or user-replaceable, and/or the channel is configured as a replaceable cylinder.
  • Typical non-regenerating devices are similar to the devices shown in Figure 1A-1C, however, will not provide second conduits for regeneration fluid.
  • the second conduit in the device of Figure 1 is entirely omitted and a sealing plate or other sealing implement will seal off the lower conduit.
  • the Archimedean screw configuration of Figure 1B is simplified in that the perpendicular in- and outlet ports can be omitted. In such case, it is generally preferred that two linear conduits will have two independent Archimedean screws with one screw operating while the other screw is not operating and replaceable. Increased incubation time is then achieved by discontinuous rotation, or by addition of a second (third, or higher) screw that operates in a parallel and alternating mode.
  • the device configuration is again simplified by providing one or more flow channels through the reciprocating block. Reciprocating movement of the block will then position a volume of whole blood in a channel between sealing surfaces for a predetermined time to allow longer incubation, and reversal of that movement (or additional forward movement) will then move the treated volume back into circulation.
  • contemplated devices are configured to be wearable, and that the reciprocating or rotating element can be readily exchanged, preferably by a non-medical professional (e.g., end user or caretaker).
  • the device has a housing that encloses at least partially the element and conduits. Fluid lines from the patient's circulation and/or regeneration fluid are preferably attachable via luer lock or other suitable connector that preferably allows maintaining sterile working conditions.
  • the regeneration fluid and other fluids, including wash fluids
  • the device may include more than one rotating or reciprocating element and/or that there are more than one type of affinity agent in one or more channels.
  • contemplated devices and methods are not limited to those having only two conduits, but any number of conduits are deemed suitable. Additional conduits may be used for measurement of one or more analytes in the whole blood and/or the regeneration fluid, and/or for provision of wash fluids and/or pharmaceutical agent.
  • contemplated device may also implement additional functionalities using a flow splitter that may be upstream or downstream, of the wheel (with respect to the flow of the whole blood). The so produced bypass or slipstream can then be treated or analyzed as desired, and fed back to the circulation or be discarded into a typically disposable waste container.
  • the conduit may include or may be coupled to a surge compartment to accommodate discontinuous flow and to maintain constant flow rate through the device.
  • contemplated devices may have a continuously operating pump, a pump that operates in on-off mode, or no pump at all.
  • the whole blood may be driven by an active pump (e.g., peristaltic, piston, etc.), or passively by a blood pressure driven mechanism.
  • the reciprocating or rotating element is actuated by a motor or other actuator, preferably in a continuous manner at constant speed.
  • the speed of the rotating or reciprocating element may also be variable and/or in an intermittent pattern.
  • channels may vary considerably and will predominantly be determined by the desired flow rate of whole blood through the element, the quantity of target compound in the whole blood, and affinity of the target compound. It is generally preferred that the channels are formed to reduce or even entirely avoid turbulent flow. Thus, channels are preferably linear or helical with a larger-than-capillary diameter (e.g., at least 50 micron, more preferably at least 100 micron, and most preferably at least 250 micron). It is further noted that the transition of a channel from blood to regeneration fluid may include a rinse step in the device and/or via a flow loop with one or more valves. Thus, most preferably, loss of whole blood is avoided as the volume of whole blood in the channel may be recycled back to the mammal (e.g., using isotonic fluid as a wash fluid).
  • Sealing of the movable element against fluid and blood loss can be achieved in numerous manners well known in the art. For example, rotary seals, rubber lip seals, or bore seals with O-rings are deemed suitable for use herein. Similarly, press-fit tolerance may be employed to reduce leakage of the channel/conduit interface.
  • IL-8/CRP reduction is performed on-line in a continuous manner using a wearable device, such as the device described herein.
  • the device can be used to remove other antigens and small molecules from whole blood by passing the blood through channels, which comprise an affinity agent to bind to the target compound.
  • IL-8 and CRP levels are elevated in whole blood of a patient undergoing taxane (e.g ., paclitaxel or decetaxel) chemotherapy, for example, in the treatment of pancreatic cancer.
  • taxane e.g ., paclitaxel or decetaxel
  • Such treatment may be in combination with other drugs, for example, gemzitabine.
  • chemotherapy in such and similar cases is not well tolerated and a significant fraction of patients will discontinue treatment due to the severe side effects.
  • IL-8 and CRP levels in patients about to discontinue chemotherapy is well above normal reference ranges, typically at least 25%, and most typically at least 50% above the upper range of normal, and contemplate that continuous reduction of the elevated levels, preferably back to reference range, will increase the level of compliance. It is generally preferred that the continuous treatment will extend over a period of at least 12 hours, more typically at least 24 hours, and most typically over at least 3 days. Thus, and viewed from another perspective, it is contemplated that the reduction of IL-8 and/or CRP will be effected over a period that coincides with at least a portion of time over which elevated levels will be observed without treatment.
  • IL-8 and/or CRP are not intended as a treatment modality of the underlying disease, but as a palliative treatment of a condition that is brought about by pharmacological intervention.
  • methods presented herein are targeted to improve subjective well-being of a patient, and especially relieve nausea, flu-like symptoms, loss of appetite, and physical and/or metal fatigue.
  • contemplated methods may be effective not only in combating side effects of chemotherapy of various neoplastic diseases, but also infectious diseases and especially including viral diseases (and particularly influenza virus, H1N1 flu, SARS, etc.), chronic inflammatory diseases (e.g., COPD, rheumatoid arthritis, inflammatory bowel disease, psoriasis, etc.), atherosclerosis, and acute coronary syndrome.
  • viral diseases and particularly influenza virus, H1N1 flu, SARS, etc.
  • chronic inflammatory diseases e.g., COPD, rheumatoid arthritis, inflammatory bowel disease, psoriasis, etc.
  • atherosclerosis e.g., atherosclerosis, and acute coronary syndrome.
  • the chemotherapeutic agent may vary considerably.
  • the pharmaceutical treatment will include chemotherapy for various neoplastic diseases, and especially those agents that are known to be associated with an increase in IL-8 and/or CRP.
  • contemplated chemotherapies may include administration of one or more of receptor antibodies, alkylating agents, antimetabolites, microtubule inhibitors (and especially taxanes), topoisomerases, and kinase inhibitors.
  • contemplated methods may be implemented on an intermittent or continuous basis, and it is generally contemplated that the reduction in IL-8 and/or CRP is performed as long as excessive levels of IL-8 and/or CRP are measured or anticipated.
  • reduction of IL-8 may be performed in a continuous manner over two days.
  • the increase is relatively brief, reduction may be performed in a discontinuous manner immediately following administration of the chemotherapeutic agent.
  • the elevated levels of IL-8 and/or CRP are, for example, due to a chronic inflammatory condition, continuous reduction in IL-8 and/or CRP may be advisable.
  • Removal is preferably monitored to achieve a continuous IL-8 and/or CRP level that is within the normal reference range (and in some cases below or slightly above).
  • the clinical range of IL-8 is typically between 10-80 pg/ml for a healthy person, and it is typically preferred that reduction of IL-8 is to equal or less than 100 pg/ml, and more preferably to equal or less than 80 pg/ml.
  • the clinical normal range for CRP is between 0-5 mg/I for male and 0-8 for female healthy adults, and it is typically preferred that reduction of CRP is to equal or less than 5 mg/I, more preferably to equal or less than 3 mg/I, and most preferably to equal or less than 1 mg/I.
  • Reduction of IL-8 and/or CRP is preferably effected via specific antibodies (e.g., HuMab 10F8 for IL-8), or other known IL-8 binders, including glycosaminoglycan (GAG) heparin, protease inhibitor alpha2-macroglobulin, Cyclosporin A, however, engineered binding agents are also deemed suitable, including recombinant IL-8 receptor and fragments thereof.
  • specific antibodies e.g., HuMab 10F8 for IL-8
  • IL-8 binders including glycosaminoglycan (GAG) heparin, protease inhibitor alpha2-macroglobulin, Cyclosporin A
  • GAG glycosaminoglycan
  • Cyclosporin A Cyclosporin A
  • engineered binding agents are also deemed suitable, including recombinant IL-8 receptor and fragments thereof.
  • CRP can be reduced by binding of CRP to one or more types of monoclonal or polyclonal antibodies, Fc receptors (e.g., FcyRIla), etc., and the number of binding agents needed to reduce the IL-8 and/or CRP levels will preferably be chosen such that continuous treatment for at least 2, and more typically 4 consecutive days is possible without patient intervention.
  • Fc receptors e.g., FcyRIla
  • the device may also be used to target other cellular components and extracellular components, such as proteins, fats and small molecules, and may also be used to target cells.
  • the whole blood treatment device can also be used to treat various diseases that are caused by one or more target compounds. Examples of these disease include treating cancer by reducing inhibitory checkpoint molecules or removing cancer cells, autoimmune diseases by reducing inflammatory factors, cardiovascular disease by reducing low-density lipoprotein, metabolic diseases such as diabetes by reducing glucose, viral infection and bacterial infection by reducing the amount of virus, bacteria or associated toxin, and toxin exposure and heavy metal exposure by removing the toxin or heavy metal.
  • Such diseases may be treated with the device by determining a target compound that can be removed from the body, and determining an affinity agent that binds to the target compound.
  • Antibodies or aptamers suited to binding the selected target compound could be used as the affinity agents, but it is understood that other compounds could also be used.
  • Inhibitory checkpoint molecules are secreted by cancer cells to reduce the immune response.
  • There are several antibody drugs referred to as immune checkpoint inhibitors or immune checkpoint blockades) that target these inhibitory checkpoint molecules in order to increase the immune response to cancer cells.
  • immune checkpoint inhibitors referred to as immune checkpoint blockades
  • the whole blood treatment devices pass whole blood through channels with a surface modified with affinity agents, where the inhibitory checkpoint molecules are bound by the affinity agents, and removed from the blood, reducing the concentration of inhibitory checkpoint molecules in the blood.
  • inhibitory checkpoint molecules are cytotoxic T-lymphocyte associated protein 4 (CTLA-4), programmed cell death-1 (PD-1), programmed death-ligand 1 (PD-L1), B7-1, B7-2, FOXP3+, FOXP3-, Treg 17, Tr1 , Th3, IL-10, and TGF- b.
  • CTL-4 cytotoxic T-lymphocyte associated protein 4
  • PD-1 programmed cell death-1
  • PD-L1 programmed death-ligand 1
  • B7-1, B7-2 programmed death-ligand 1
  • FOXP3+ FOXP3-
  • Treg 17, Tr1 , Th3, IL-10 TGF- b
  • TGF- b TGF- b
  • antibody drugs that could be used as affinity agents include ipilimumab, ticilimumab, pembrolizumab, atezolizumab and nivolumab, along with many others, as described in Ghirelli et al. (“Target
  • Inflammatory factors are often reduced using antibody drug treatments.
  • Inflammatory factors may include IL-4, IL-10, TNFcr, IL-17A, IL-17F, CRP, TNF, IL-1o, IL-Ib, IL-5, IL-6, IL- 8, IL-12, IL-23, CD2, CD3, CD20, CD22, CD52, CD80, CD86, C5 complement protein, BAFF, APRIL, IgE, a4b1 integrin and a4b7 integrin.
  • IL-17A/F antibodies abatacept, alefacept, alemtuzumab, atacicept, belimumab, canakinumab, eculizumab, epratuzumab, natalizumab, ocrelizumab, ofatumumab, omalizumab, otelixizumab, rituximab, teplizumab, vedolizumab, adalimumab, briakinumab, certolizumab pegol, eta Percept, golimumab, infliximab, mepolizumab, reslizumab, tocilizumab and ustekinumab.
  • viruses can be targeted using various drugs. However, removing these from the blood, via a whole blood treatment device would reduce unintended side effects.
  • the target compounds can include viruses and cells infected with viruses. Examples of viruses include chickenpox, flu (influenza), herpes, human immunodeficiency virus (HIV/AIDS), human papillomavirus (HPV), infectious mononucleosis, mumps, measles, rubella and shingles.
  • Antibodies that bind to these viruses may be used as the affinity agent, and can be prepared by well-known methods.
  • Antibodies can be used to treat various cancers. Rather than using antibodies that bind cancer cells as a drug, these antibodies can be used in a channel of a whole blood treatment device. Examples of cancer cells include skin, breast, lung, pancreas, kidney, leukemia, lymphoma, and many other types of cancer. For example, treatment of cancer can be carried out by targeting cells displaying nucleolin on the cell surface. Anti-nucleolin antibodies can bind to the nucleolin on the surface of the cancer cell.
  • anti-nucleolin antibodies include p7-1A4 mouse monoclonal antibody, sc-8031 mouse mAb, sc-9893 goat polyclonal Ab (pAb), sc-9892 goat pAb, clone 4E2 mouse mAb, and clone 3G4B2 mouse mAb, which may be used as affinity agents.
  • antibody drugs to treat cancer cells which may be used as affinity agents include alemtuzumab, trastuzumab, Ibritumomab tiuxetan, Brentuximab vedotin, Ado-trastuzumab emtansine, denileukin diftitox, and blinatumomab, along with other can be found in American Cancer Society; Monoclonal Antibodies to Treat Cancer (available at www.cancer.org/treatment/treatments-and-side-effects/treatment- types/immunotherapy/monoclonal-antibodies.html). Other drugs may be used to bind cancer cells within the device.
  • Heavy metal poisoning may be treated with a whole blood treatment device to reduce the concentration of heavy metals to a safe level.
  • Heavy metals may include lead, mercury, arsenic and cadmium. These metals can be bound by an affinity agent such as DNAzyme as described in Zhang et al. (“Metal Ion Sensors Based on DNAzymes and Related DNA Molecules” Annual review of analytical chemistry 2011 ;4(1):105-128). Chelating agents could also be used as an affinity agent to bind to the target compounds in the device.
  • Alzheimer’s disease can be treated with solanezumab. Rather than administering this drug to a patient, a whole blood treatment device can be used to filter target compounds from whole blood, using the antibody as an affinity agent. Some examples of target compounds for Alzheimer’s disease include misfolded amyloid beta and tau proteins.
  • Bacteria and toxins in the bloodstream can be treated with various drugs. Rather than administering these drugs to a patient, a whole blood treatment device can be used to filter the bacteria or toxins from whole blood.
  • Antibodies and aptamers may be used as affinity agents for the bacteria or toxins. Such antibodies and aptamers may be prepared by well-known methods.
  • cytokines including tumor necrosis factor (TNF) and interleukin 1
  • TNF tumor necrosis factor
  • interleukin 1 interleukin 1
  • TNF tumor necrosis factor
  • inhibitory checkpoint molecules are also present in increased concentration in the blood of patients with sepsis.
  • Methanol poisoning can be treated by competitive inhibition. Methanol concentration could also be reduced using the whole blood treatment device with affinity agents such as aptamers.
  • Heroin overdoses can be treated by various drugs. Rather than administering these drugs, a whole blood treatment device could be used to reduce the concentration of opioids in the blood. Antibodies, aptamers or other compounds may be used as affinity agents for the opioids.
  • Monoclonal antibodies are usually made by fusing mouse spleen cells immunized with a desired antigen with myeloma cells (B-cell cancer cells, which are known for producing antibodies). The fused cells are transferred to a medium that is selective for fused cells. Several cell cultures are then grown from single parent cells. The antibodies from the different parent cells are then assayed using well-known methods such as ELISA to determine the antibodies ability to bind the antigen. [0040] It would be understood by those skilled in the art, that the systematic evolution of ligands by exponential enrichment (SELEX) technique, or similar techniques, could be used to produce aptamers that specifically bind or target compounds or cells.
  • SELEX systematic evolution of ligands by exponential enrichment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • External Artificial Organs (AREA)

Abstract

Un dispositif de traitement du sang total comprend un premier conduit, un second conduit et un élément rotatif ou à mouvement alternatif comportant un canal. Les premier et second conduits sont en accouplement fluidique avec l'élément rotatif ou à mouvement alternatif, de sorte que le canal soit en communication fluidique avec le premier conduit lorsque le canal n'est pas en communication fluidique avec le second conduit, et de sorte que le canal ne soit pas en communication fluidique avec le premier conduit lorsque le canal est en communication fluidique avec le second conduit. Le premier conduit est conçu pour recevoir du sang total, et le second conduit est conçu pour recevoir un fluide de régénération. Le canal comprend une surface modifiée à l'aide d'un agent d'affinité à une concentration efficace pour permettre l'élimination d'un composé cible à partir du sang total.
PCT/US2020/039056 2020-06-23 2020-06-23 Dispositifs et procédés de traitement de sang total en ligne WO2021262147A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2020/039056 WO2021262147A1 (fr) 2020-06-23 2020-06-23 Dispositifs et procédés de traitement de sang total en ligne

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/039056 WO2021262147A1 (fr) 2020-06-23 2020-06-23 Dispositifs et procédés de traitement de sang total en ligne

Publications (1)

Publication Number Publication Date
WO2021262147A1 true WO2021262147A1 (fr) 2021-12-30

Family

ID=71528098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/039056 WO2021262147A1 (fr) 2020-06-23 2020-06-23 Dispositifs et procédés de traitement de sang total en ligne

Country Status (1)

Country Link
WO (1) WO2021262147A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048483A1 (fr) * 1996-06-20 1997-12-24 Baxter International Inc. Systeme a membranes d'affinite et son procede d'utilisation
US6143510A (en) 1994-07-29 2000-11-07 Iatron Laboratories Inc. Measuring method using whole blood sample
US20090114595A1 (en) 2005-02-16 2009-05-07 Triomed Ab System and Method for Regeneration of a Fluid
WO2009072003A2 (fr) * 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Système et procédés de traitement d'échantillons
WO2011005742A1 (fr) 2009-07-06 2011-01-13 Mar Systems, Llc Milieux pour l'élimination de contaminants à partir de courants de fluides et procédé de fabrication et d'utilisation de ceux-ci
JP2016195590A (ja) * 2015-04-03 2016-11-24 株式会社カネカ 細胞分離機器用コネクタ、コネクタを配した細胞分離フィルター、及び細胞分離フィルターを利用した細胞濃縮液の製造方法
EP3533507A1 (fr) * 2011-08-10 2019-09-04 New Health Sciences, Inc. Dispositif de filtre de séparation intégré de plasma et de leucocytes à appauvrissement en oxygène et/ou en co2
US10744258B1 (en) * 2017-03-06 2020-08-18 Qualigen Inc. Devices and methods for on-line whole blood treatment

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143510A (en) 1994-07-29 2000-11-07 Iatron Laboratories Inc. Measuring method using whole blood sample
WO1997048483A1 (fr) * 1996-06-20 1997-12-24 Baxter International Inc. Systeme a membranes d'affinite et son procede d'utilisation
US20090114595A1 (en) 2005-02-16 2009-05-07 Triomed Ab System and Method for Regeneration of a Fluid
WO2009072003A2 (fr) * 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Système et procédés de traitement d'échantillons
WO2011005742A1 (fr) 2009-07-06 2011-01-13 Mar Systems, Llc Milieux pour l'élimination de contaminants à partir de courants de fluides et procédé de fabrication et d'utilisation de ceux-ci
EP3533507A1 (fr) * 2011-08-10 2019-09-04 New Health Sciences, Inc. Dispositif de filtre de séparation intégré de plasma et de leucocytes à appauvrissement en oxygène et/ou en co2
JP2016195590A (ja) * 2015-04-03 2016-11-24 株式会社カネカ 細胞分離機器用コネクタ、コネクタを配した細胞分離フィルター、及び細胞分離フィルターを利用した細胞濃縮液の製造方法
US10744258B1 (en) * 2017-03-06 2020-08-18 Qualigen Inc. Devices and methods for on-line whole blood treatment

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHAN, A.C. ET AL.: "Therapeutic antibodies for autoimmunity and inflammation", NATURE REVIEWS IMMUNOLOGY, vol. 10, 2010, pages 301 - 316, XP002665072, DOI: 10.1038/NRI2761
FOCOSI ET AL.: "Immunosuppressive monoclonal antibodies: current and next generation", CLIN MICROBIOL INFECT, vol. 17, 2011, pages 1759 - 1768, XP055079688, DOI: 10.1111/j.1469-0691.2011.03677.x
GHIRELLI ET AL.: "Targeting immunosuppression for cancer therapy", J CLIN INVEST., vol. 123, no. 6, 2013, pages 2355 - 2357
HOTCHKISS ET AL.: "Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach", THE LANCET INFECTIOUS DISEASES, vol. 13, no. 3, 2013, pages 260 - 268
ZHANG ET AL.: "Metal Ion Sensors Based on DNAzymes and Related DNA Molecules", ANNUAL REVIEW OF ANALYTICAL CHEMISTRY, vol. 4, no. 1, 2011, pages 105 - 128

Similar Documents

Publication Publication Date Title
US20200397985A1 (en) Devices and methods for on-line whole blood treatment
AU2009227872B2 (en) Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients
US8834400B2 (en) Artificial kidney
EP0111696B1 (fr) Agencement pour l'élimination d'une ou plusieurs fractions du sang, du plasma ou d'autres liquides similaires du corps humain
US8449489B2 (en) Method and means for treating inflammatory bowel disease
US20120323158A1 (en) Extracorporeal immunoadsorption treatment
WO2011133287A1 (fr) Dispositifs et systèmes portatifs de filtration sanguine, et méthodes associées
US20220143291A1 (en) Whole blood treatment device and methods of removing target agents from whole blood
WO2010030789A1 (fr) Dispositif et procédé pour l'inhibition de l'activation du complément
AU2022203249B2 (en) System and method for removal of immune inhibitors from biological fluids
WO2021262147A1 (fr) Dispositifs et procédés de traitement de sang total en ligne
US20220362450A1 (en) Assembly for extracorporeal treatment of body fluids
CN115052677A (zh) 碱金属氢氧化物溶液用于单采柱再生的用途
US20230321412A1 (en) System and method for managing cancer cells in csf
TWI762833B (zh) 自生物流體中移除免疫抑制劑之系統及方法
Horton et al. The use of therapeutic apheresis in allergic and immunological diseases
WO2022005925A1 (fr) Dispositifs et procédés de traitement ou de prévention du syndrome de libération de cytokines et du syndrome de lyse tumorale
WO2009155538A1 (fr) Compositions et méthodes permettant d'épuiser des peptides bêta-amyloïdes provenant du liquide cérébro-spinal pour le traitement de la maladie d'alzheimer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20737831

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20737831

Country of ref document: EP

Kind code of ref document: A1